Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus INFANT S ADVIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus INFANT S ADVIL.
CHILDREN'S IBUPROFEN vs INFANT'S ADVIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
200-400 mg orally every 4-6 hours as needed; maximum daily dose 1200 mg.
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Terminal elimination half-life is approximately 1.5 to 2 hours in infants and children, which is shorter than in adults (2-4 hours). This shorter half-life reflects higher clearance in pediatric populations and has clinical implications for dosing frequency (typically every 6-8 hours).
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Renal excretion of metabolites (primarily glucuronide and sulfate conjugates of ibuprofen) accounts for approximately 90% of elimination, with less than 10% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Category D/X
Category C
NSAID
NSAID